J Clin Oncol: Efficacy and safety of T-DM1 + ​​Pertuzumab vs. Taxanes + Trastuzumab + Pertuzumab in the treatment of high-risk HER2+ early breast cancer patients: Phase III clinical study KAITLIN

Anti-HER2 therapy is the basic treatment for patients with HER2-positive breast cancer
.
Recently, the Journal of Clinical Oncology published the results of a phase III clinical study KAITLIN (NCT01966471), which compares T-DM1+pertuzumab with taxanes+trax in high-risk HER2+ early breast cancer (EBC) patients Efficacy and safety of touzumab+pertuzumab treatment

.

Anti-HER2 therapy is the basic treatment for patients with HER2-positive breast cancer

KAITLIN (NCT01966471) included HER2-positive EBC (positive or negative lymph node, negative hormone receptor, tumor> 2cm)

.

KAITLIN (NCT01966471) included HER2-positive EBC (positive or negative lymph node, negative hormone receptor, tumor> 2cm)

From January 2014 to June 2015, a total of 1846 patients were enrolled (918 cases in the AC-THP group; 928 cases in the AC-KP group)

Among patients with positive lymph nodes, AC-KP treatment did not reduce the risk of IDFS in the subgroup of patients with positive lymph nodes compared with AC-THP (HR, 0.

IDFS of the two treatment groups for lymph node positive and the general population

IDFS of the two treatment groups for lymph node positive and the general population

In the pre-designated exploratory subgroup analysis, except for the differences in IDFS of breast-conserving surgery, IDFS among different subgroups was consistent and similar

.

In the pre-designated exploratory subgroup analysis, except for the differences in IDFS of breast-conserving surgery, IDFS among different subgroups was consistent and similar

IDFS for subgroup analysis

IDFS for subgroup analysis

AC-THP and AC-KP group ≥3 grade AEs were similar

.

AC-THP and AC-KP group ≥3 grade AEs were similar

AEs

In summary, studies have shown that T-DM1 + ​​Pertuzumab (AC-KP) does not improve patient IDFS than taxane + Trastuzumab + Pertuzumab (AC-THP)

.

In summary, studies have shown that T-DM1 + ​​Pertuzumab (AC-KP) does not improve patient IDFS than taxane + Trastuzumab + Pertuzumab (AC-THP)
.
AC-THP is still the standard treatment
.
Studies have shown that T-DM1 + ​​Pertuzumab (AC-KP) does not improve patient IDFS than taxane + Trastuzumab + Pertuzumab (AC-THP)
.
AC-THP is still the standard treatment
.
Studies have shown that T-DM1 + ​​Pertuzumab (AC-KP) does not improve patient IDFS than taxane + Trastuzumab + Pertuzumab (AC-THP)
.
AC-THP is still the standard treatment
.

Original source:

Original source:

Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis PA, Gianni L, Swain SM, Im YH, De Laurentiis M, Nowecki Z, Huang CS, Fehrenbacher L, Ito Y, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer EP, Harbeck N.
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
J Clin Oncol.
2021 Dec 10:JCO2100896.
doi: 10.
1200/JCO.
21.
00896.
Epub ahead of print.
PMID: 34890214.

Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis PA, Gianni L, Swain SM, Im YH, De Laurentiis M, Nowecki Z, Huang CS, Fehrenbacher L, Ito Y, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer EP, Harbeck N.
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
J Clin Oncol.
2021 Dec 10:JCO2100896.
doi: 10.
1200/JCO.
21.
00896.
Epub ahead of print.
PMID: 34890214.
Leave a message here